Literature DB >> 28246429

Phosphate binders in patients with chronic kidney disease.

Samuel Chan1, Kenneth Au2, Ross S Francis3, David W Mudge3, David W Johnson4, Peter I Pillans5.   

Abstract

Entities:  

Keywords:  chronic kidney disease; drug compliance; drug costs; hyperphosphataemia; phosphate binders; pill burden

Year:  2017        PMID： 28246429      PMCID： PMC5313253          DOI： 10.18773/austprescr.2017.002

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  54 in total

1.  The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification.

Authors:  G London; D Coyne; K Hruska; H H Malluche; K J Martin
Journal:  Clin Nephrol       Date:  2010-12       Impact factor: 0.975

2.  Impact of phosphate binder type on coronary artery calcification in hemodialysis patients.

Authors:  R Shantouf; N Ahmadi; F Flores; J Tiano; A Gopal; K Kalantar-Zadeh; M J Budoff
Journal:  Clin Nephrol       Date:  2010-07       Impact factor: 0.975

3.  Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.

Authors:  David Pierce; Stuart Hossack; Antoine Robinson; Pinggao Zhang; Patrick Martin
Journal:  Clin Ther       Date:  2012-05-31       Impact factor: 3.393

4.  Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

Authors:  A J Hutchison; M E Barnett; R Krause; G A Siami
Journal:  Clin Nephrol       Date:  2009-03       Impact factor: 0.975

5.  Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.

Authors:  Suetonia C Palmer; Sharon Gardner; Marcello Tonelli; Dimitris Mavridis; David W Johnson; Jonathan C Craig; Richard French; Marinella Ruospo; Giovanni F M Strippoli
Journal:  Am J Kidney Dis       Date:  2016-07-22       Impact factor: 8.860

6.  Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.

Authors:  M J Janssen; A van der Kuy; P M ter Wee; W P van Boven
Journal:  Clin Nephrol       Date:  1996-02       Impact factor: 0.975

7.  Phosphorus binders and survival on hemodialysis.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Yuchiao Chang; Anand Shah; Hector Tamez; Kelsey Smith; Ravi Thadhani; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

8.  Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin.

Authors:  Priscilla P How; James H Fischer; Jose A Arruda; Alan H Lau
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-03       Impact factor: 8.237

9.  Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.

Authors:  B Jespersen; J D Jensen; H K Nielsen; I N Lauridsen; M J Andersen; J H Poulsen; B Gammelgaard; E B Pedersen
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

Review 10.  Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.

Authors:  Adrian Covic; Prajesh Kothawala; Myriam Bernal; Sean Robbins; Arpi Chalian; David Goldsmith
Journal:  Nephrol Dial Transplant       Date:  2008-11-11       Impact factor: 5.992
View more
  12 in total

Review 1.  A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.

Authors:  Dengpiao Xie; Naijing Ye; Mingquan Li
Journal:  Int Urol Nephrol       Date:  2018-01-02       Impact factor: 2.370

Review 2.  An update on vascular calcification and potential therapeutics.

Authors:  Anubha Singh; Simran Tandon; Chanderdeep Tandon
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

3.  Interpretation of Parathyroid Hormone Levels in Renal Impairment.

Authors:  Ifeanyi F Nwosu; Cece E Ibeson; Adedoyin Olawoye; Htin Kyaw; Kelash Kumar; Celestine Odigwe; Chukwunonso A Nwosu; Anthony Oshunsanya
Journal:  Cureus       Date:  2022-06-10

4.  Phosphate binders usage, patients knowledge, and adherence. A cross-sectional study in 4 centers at Qassim, Saudi Arabia.

Authors:  Alanoud M Aleidi; Nouf J Alayed; Htoon M Alduraibi; Najd S Alqassimi; Amal A Ismail
Journal:  Saudi Med J       Date:  2020-10       Impact factor: 1.484

5.  Doxycycline reduces osteopenia in female rats.

Authors:  Fellipe A T de Figueiredo; Roberta C Shimano; Edilson Ervolino; Dimitrius L Pitol; Raquel F Gerlach; Joao Paulo M Issa
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

6.  Phosphate restriction using a processed clay mineral reduces vascular pathologies and microalbuminuria in rats with chronic renal failure.

Authors:  Jacqueline Hofrichter; Kai Sempert; Claus Kerkhoff; Anne Breitrück; Reinhold Wasserkort; Steffen Mitzner
Journal:  BMC Nephrol       Date:  2022-04-28       Impact factor: 2.585

7.  Use of Phosphate Binders in End-Stage Renal Disease: An Experience From a Secondary Care Hospital in United Arab Emirates.

Authors:  Syed Arman Rabbani; Sathvik B Sridhar; Padma G M Rao; Martin T Kurian; Basset E Essawy
Journal:  J Pharm Bioallied Sci       Date:  2019 Apr-Jun

8.  The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts.

Authors:  Carla Viegas; Nuna Araújo; Catarina Marreiros; Dina Simes
Journal:  Aging (Albany NY)       Date:  2019-06-26       Impact factor: 5.682

Review 9.  The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis.

Authors:  Joanne Marks
Journal:  Pflugers Arch       Date:  2018-10-20       Impact factor: 3.657

Review 10.  Interactions of Whey Proteins with Metal Ions.

Authors:  Agnieszka Rodzik; Paweł Pomastowski; Gulyaim N Sagandykova; Bogusław Buszewski
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.